الفهرس 
Clinico-pharmacological study of low dose capecitabine and oxaliplatin versus standard XELOX in metastatic colorectal cancer
في علاج أورام القولون والمستقيم المتقدمه XELOXدراسه فارما إكلينيكيه لمقارنه إستخدام الكابسيتبين والأوكسالبلاتين بجرعات منخفضه وإستخدام برتوكولOnly 14 pages are availabe for public view
 |  | from | 193 |  |  |
| | | from | 193 | | |
Abstract
Background: Colorectal cancer (CRC) is the fourth most common human malignancy, and the leading cause of cancer related deaths worldwide. Conventional chemotherapy is normally administered near the maximal tolerated dose while metronomic chemotherapy refers to more frequent administration of chemotherapeutics at doses significantly less than the maximum tolerated dose, with no prolonged drug-free breaks Aims: To compare between low dose metronomic chemotherapy with Capecitabine and Oxaliplatin is and classic XELOX in treatment of metastatic Colorectal cancer regarding response rates, toxicity and pharmacokinetics. Methods:This is a randomized phase II prospective cohort study that included 70 metastatic colo-rectal cancer patients diagnosed at National Cancer Institute (NCI), Cairo University between January 2016 and June 2017. Results: The median duration of the treatment for each arm was 6 months.Toxicity occurred in 26 cases (75 % of arm A) and 21 cases (60% of arm B), The median TTP for patients receiving arm A was 7.6 months while the patients receiving arm B had median TTP 5.7 months (P=0.318) while the median OS for Arm A 15.9 and for Arm B (15.8) (p=0.8) that is insignificant.Conclusion: Metronomic protocol was associated with lower rates of toxicity, better pharmacokinetics profile without improvements in PFS or OS